TVGN insider trading
NasdaqGM HealthcareTevogen Inc.: insider trade history from SEC Form 4 filings.
About Tevogen Inc.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Company website: tevogen.com
TVGN insider activity at a glance
FilingIQ tracks 53 insider transactions for TVGN in filings since Feb 16, 2024. The most recent transaction is dated Sep 14, 2026.
Across the full history, 2 open-market purchases
and 12 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest TVGN Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TVGN?
- FilingIQ tracks 53 Form 4 insider transactions for TVGN (Tevogen Inc.), covering filings from Feb 16, 2024 onwards. 7 of those are dated within the last 90 days.
- Are TVGN insiders net buyers or net sellers?
- Across the full Form 4 history for TVGN, 2 transactions (4%) were open-market purchases and 12 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TVGN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is TVGN in?
- Tevogen Inc. (TVGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $20.93M.
Methodology & sources
Every TVGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.